Stellato D, Gerbasi ME, Ndife B, Ghate SR, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE. Budget impact of Dabrafenib and Trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a U.S. commercial payer perspective. J Manag Care Spec Pharm 2019;(11):1227-37. | PAI - Policy Analysis Inc.

Stellato D, Gerbasi ME, Ndife B, Ghate SR, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE. Budget impact of Dabrafenib and Trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a U.S. commercial payer perspective. J Manag Care Spec Pharm 2019;(11):1227-37. | PAI - Policy Analysis Inc.